Background and Aims: Postprocedural bleeding (PPB) is the most common adverse event associated with endoscopic resection. Several studies have tried to identify risk factors for PPB after gastric EMR and endoscopic submucosal dissection (ESD), with controversial results. This systematic review and meta-analysis aimed to identify significant risk factors for PPB after gastric EMR and ESD.
hemorrhage). Queries for other databases were adapted from this query. Additional studies were identified by checking the list of references of all included studies and reviews on the topic.
Two independent investigators (D.L., M.N.C.) screened titles and abstracts to exclude irrelevant studies. The full text of relevant studies was then analyzed by these same authors according to the criteria below. Disagreements were solved by consensus with the intervention of a third reviewer (P.P.N.) when required. This phase was performed with Covidence online platform (www.covidence. org).
Abstracts and fully published studies were considered for inclusion with no date or language restrictions. Inclusion criteria were (1) retrospective or prospective, case-control or cohort studies and clinical trials (including randomized controlled trials [RCTs]); (2) studies evaluating patients submitted to EMR or ESD to treat gastric superficial neoplasms (dysplastic lesions or early gastric cancers); (3) studies with PPB rates reported separately from intraprocedural bleeding; and (4) studies where risk factors for PPB were analyzed. Articles were excluded if (1) PPB rates were not clearly reported; (2) fewer than 20 patients were included; (3) they were feasibility studies of innovative techniques/devices without control group; (4) they were comments, reviews, letters, or surveys; (5) they were case reports; or (6) they were animal studies.
Quality evaluation and data extraction
Data extraction and quality assessment were performed by D.L. using prespecified forms that were refined after piloting in 10 studies. Another reviewer (M.N.C.) independently checked the extracted data, and disagreements were solved by consensus. Data extraction forms included (1) author, (2) publication year, (3) setting, (4) study period, (5) study design, (6) randomization methods if applicable, (7) allocation concealment, (8) blinding, (9) type of endoscopic resection (EMR/ESD), (10) number of participants, (11) definition of PPB, (12) frequency of PPB (total and for each risk factor), (13) antacids (route, dosage, duration of therapy), (14) antithrombotic management, (15) operator (single/multiple, experienced/nonexperienced), and (16) second-look endoscopy (SLE). In the data extraction form, crude data and results of statistical analysis were recorded for each risk factor. Quality evaluation was performed using the Cochrane risk of bias tool for RCTs 5 and the Newcastle-Ottawa scale for observational studies. 6 Also, the quality of reporting of acid inhibition strategy and antithrombotic management was assessed.
Data synthesis and statistical analysis
Odds ratios (ORs) and 95% confidence intervals (CIs) for each categoric risk factor and the mean or median for continuous data was registered (or calculated whenever possible). Studies providing data allowing the calculation of ORs were then included in a meta-analysis, performed by computing pooled ORs (for categoric variables) and mean differences (for continuous variables) using a random-effects model. Pooled PPB prevalence was calculated with a random-effects model with OpenMetaAnalyst. 7 Meta-analysis was performed using RevMan 5.3. 8 Heterogeneity was evaluated with the Cochran Q test and I 2 . Significant heterogeneity was defined as I 2 > 40% and P < .05. For continuous outcomes, median and interquartile range/range were transformed into mean and standard deviation through the methods proposed by the Cochrane collaboration and Hozo et al. 9 Sensitivity analysis was planned, excluding these studies and whenever significant heterogeneity was found. Subgroup analysis was planned according to study design, time of bleeding (early or delayed), and antithrombotic management. This study was conducted in accordance with the PRISMA recommendations for reporting systematic reviews and meta-analysis. 10 
RESULTS

Characteristics of included studies and quality evaluation
In total, 1043 studies were identified (1038 through database search and 5 through manual searching), and 74 references (71 studies) were finally included in this systematic review (Fig. 1) . A summary of the included studies and quality evaluation (15 RCTs, 3 prospective trials, 5 prospective cohort studies, and 48 retrospective cohort and case-control studies) is shown in Table 1 . Seventy-three percent of RCTs were judged to have low risk of bias, whereas observational studies had a median and mean Newcastle-Ottawa score of 7 and 7.5, respectively. Almost all studies reported that proton pump inhibitors (PPI) or histamine-2 receptor antagonists (H 2 RAs) were administered in the periprocedural period, although route, dosage, frequency of administration, and duration of treatment were not accurately reported in 42% of the studies. Moreover, the management of antithrombotics was not clearly reported in 24 studies (32%).
PPB definition and rate
The most common definition of PPB was clinical evidence of bleeding (hematemesis/melena) or hemoglobin drop 2 g/dL requiring endoscopic hemostasis. Definitions of early and delayed bleeding were heterogeneous among studies, with some studies defining early bleeding as those occurring in the first 24 hours, whereas others considered early bleeding those that occurred in the first 48 hours or in the first 5 days after ESD.
PPB rates ranged from .6% 11 to 26.9%, 12 and the pooled PPB rate was 5.1% (95% CI, 4.5%-5.7%), with significant heterogeneity across studies (I 2 Z 84.46, P < .001). However, PPB rates were not significantly different according to study design (5.9% in RCTs, 6.1% in prospective studies, and 4.9% in retrospective studies; I 2 > 80%).
The time of bleeding was determined in 28 studies. Definitions of early and delayed bleeding were also heterogeneous across studies. Most bleeding episodes (213/374; 56.9%) occurred more than 24 hours after ESD. Among the 4 studies classifying early PPB as bleeding < 48 hours after ESD, 92 of 135 PPB events (68.2%) occurred in this time period. As stated below, among those studies reporting delayed bleeding (>48 hours after ESD) only, upper localization was associated with a higher bleeding risk.
Risk factors for PPB
All included studies explored risk factors for PPB after ESD, whereas risk factors for PPB after EMR were evaluated in 3 studies. Most studies (54%) evaluated multiple risk factors (case-control design), whereas 46% focused on single risk factors (eg, age, size, premedication with PPIs). Significant risk factors found in the meta-analysis are summarized in Figure 2 , and the effect estimates for each risk factor are shown in Tables 2, 3 , and 4.
Patient factors. Age was not identified as a risk factor in most studies, with only 1 study reporting that younger patients may be at higher risk for PPB. 34 Furthermore, 10 studies found no significant differences in elderly patients, 19, 25, 30, [35] [36] [37] [38] [39] [40] [41] although 1 study identified age > 80 years as an independent risk factor for PPB. 42 PPB rates were similar between genders in most studies, [13] [14] [15] [16] [17] [18] [20] [21] [22] [23] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] 36, 39, [42] [43] [44] with only 1 study reporting an association male sex associated with PPB. 24 Arterial hypertension was not identified as a risk factor in most studies, [13] [14] [15] 17, 18, [20] [21] [22] [23] [24] [28] [29] [30] [31] 33, 42, 43, 45 although 2 studies reported significantly higher PPB rates in hypertensive patients. 16, 36 However, the adjusted OR was .67 in the latter study. 36 Similarly, diabetes mellitus was not identified as a significant risk factor in any study. [13] [14] [15] [16] [17] [18] [20] [21] [22] [23] [24] [28] [29] [30] [31] 33, 34, 36, 42, 44, 45 Cardiopathy (ischemic heart disease in most studies), 10 were not identified as risk factors for PPB in most studies. Chronic kidney disease was not identified as a risk factor in some studies despite a trend to higher bleeding. 14, 17, 22, 28, 30, 34, 42 However, 3 studies found significantly increased PPB rates in patients with chronic kidney disease 45 and undergoing dialysis. 18, 46 Comorbidities 28, 45 and American Society of Anesthesiologists Physical Status Classification System status 47 were not identified to be associated with PPB, although 1 study found increased PPB risk in patients with significant comorbidities. 25 Other clinical factors were analyzed in a few studies. Helicobacter pylori infection, 13, 14, 22 body mass index, 22, 29, 36 hyperlipidemia, 24, 29, 31, 34, 42 hyperuricemia, 36 pulmonary disease, 34 history of peptic ulcer, 31 hemoglobin level, 22 prothrombin, and activated partial thromboplastin time 22, 25 were not found to be associated with PPB. Thrombocytopenia was associated with PPB in 1 study, 43 although 2 studies did not find differences in PPB rates. 16, 22 Finally, previous gastric surgery (ESD in gastric remnant or gastric tube) was not associated with increased PPB. 22, 48, 49 However, 1 study found a higher PPB rate when the anastomotic site was involved. 48 After meta-analysis, male sex, cardiopathy, cirrhosis, and chronic kidney disease were significantly associated with PPB. Among patients with chronic kidney disease, dialysis was associated with an increased PPB risk ( 16, 27, 35, 52, 53, 56, 75 did not clearly report AT management (pooled PPB, 3.6%), whereas this was adequately reported in the remaining studies.
AT was not identified as a risk factor in 17 studies. 13, 14, [16] [17] [18] [20] [21] [22] [23] [27] [28] [29] [30] [31] 36, 42, 43 However, meta-analysis showed that PPB was significantly associated with AT use (Fig. 3) . In subgroup analysis PPB risk was not significantly increased if AT were withheld 1 week before and after ESD, whereas AT resumption immediately after ESD was significantly associated with PPB. Regarding low-dose aspirin, a study found that PPB was more frequent in continuous aspirin users than in those who never used or discontinued aspirin therapy, with a trend to later bleeding. 15 On the other hand, 2 studies found no significant increase in PPB rates in patients submitted to ESD under low-dose aspirin despite a tendency to higher bleeding. 25, 26, 50 Other studies found that PPB was associated with the use of anticoagulants 51 and double AT 52, 53 but not with antiplatelet monotherapy. On the other hand, thienopyridines were associated with higher PPB risk even with discontinuation for 5 to 8 days before and resumption at a median of 3 days after ESD. 12 Heparin replacement was not identified as a significant risk factor in 1 study, 43 although an opposite result was found in another study. 40 Gastroprotective agents were associated with lower PPB in patients undergoing AT in 1 study. 54 Corticosteroid use was not identified as a risk factor for PPB. 16, 24, 43 Lesion characteristics. Tumor size and resected specimen size were evaluated as risk factors in several studies. Lesion sizes > 10 mm 55 and >20 mm 43, 56 were not found to increase PPB in some studies, whereas lesion sizes > 20 mm, 20, 22, 39, [57] [58] [59] >30 mm, 39 and >40 mm 58 were found to be associated with higher PPB risk in others. Regarding specimen size, the larger the ulcer, the higher the risk, with an artificial ulcer > 30 mm, 36 34 mm,
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>40 mm, [23] [24] [25] [26] 30, 61 and >50 mm 36, 43 identified as risk factors for PPB in diverse studies. When the studies evaluated the mean sizes of tumors and resected specimens between those with PPB and those without, the results were conflicting, with some reporting significant differences between tumor 22, 26, 34, 42 and specimen 21, 23, 24, 29, 34, 42 sizes and others not finding significant differences between the 2 groups. 13, 14, [16] [17] [18] 20, 27, 28, [31] [32] [33] 51 In addition, results concerning whether tumor location impacts PPB were controversial. Four studies reported that tumors located in the lower third 33, 34, 36, 57 and in the middle/lower third 27, 31, 37, 38 of the stomach had significantly higher bleeding rates, whereas the upper location of the stomach was found to be a significant risk factor in other studies. 30, 58 However, several studies reported no significant differences in PPB according to tumor location. [14] [15] [16] [17] [18] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] 32, 39, 42, 43, 51, 55, 61 Horizontal localization (anterior or posterior wall; lesser or greater curvature) was not found to influence PPB in individual studies. [15] [16] [17] [20] [21] [22] [23] [24] 27, 29 Regarding the relationship between
Risk factors for post-ESD bleeding Risk Factor
Chronic Kidney disease (2) Tumor > 20 mm (6) H2RA (6) ESD>60 min (3) Cirrhosis (12) Lesser curvature (9) Ulceration (18) Cardiopathy (15) Antithrombotics (22) Carcinoma (14) Flat/depressed (17) Male sex (25) Figure 2 . Significant risk factors for post-procedural bleeding after gastric ESD. In the first column, the numbers between parentheses refer to the number of studies used in the calculation of odds ratio. LCL, lower confidence limit (95%); UCL, upper confidence limit (95% time of bleeding and tumor location, lower sites were associated with earlier bleeding in 4 studies. 29, 33, 34, 62 Macroscopic type was also explored in several studies, with most finding no relation between morphology and PPB. 13, 18, [20] [21] [22] [23] [24] 28, 29, 32, 34, 39, 42, 43, 61 However, flat, 58 depressed, 16 and flat/depressed 14,17 lesions were associated with increased PPB in some studies.
Most studies did not find significant differences in PPB according to histology (dysplasia or carcinoma) 15, 18, 20, 22, 27, 28, 30, 34, 39, 42 or invasion depth (mucosal vs submucosal), 18, [22] [23] [24] [26] [27] [28] [29] [30] [31] [32] [33] [34] 42, 43 with few studies reporting a significantly increased risk of PPB in lesions harboring carcinoma 17, 25 and submucosal invasion. 14, 36 Tumor differentiation 14, 21, 24, 29, 43 and lymphovascular invasion 43 were not found to influence PPB. Expanded indication lesions were associated with higher PPB in 1 study, 63 whereas PPB was not significantly different between standard and expanded indications in 3 studies despite a tendency for higher bleeding in the latter group. 48, 64, 65 Ulceration was not associated with PPB, 14 27 Submucosal fibrosis has also been analyzed and was not identified as an independent risk factor. 13, 14, 61, 67 The presence of scarring was not identified as an influence on PPB in 3 studies, 32, 51, 58 although it was associated with higher PPB in 2 studies. 36, 59 After meta-analysis, increased tumor and specimen size, flat/depressed morphology (Fig. 4) , localization in the lesser curvature, ulceration, carcinoma histology, and expanded indication were identified as significant risk factors for PPB (Table 3) . On the other hand, vertical localization was not found to influence overall PPB, although localization in the upper third was significantly associated with PPB in the group of studies that only reported the frequency of delayed bleeding (Fig. 5) . Submucosal invasion and fibrosis/scarring were not found to influence PPB despite a tendency for higher bleeding in the latter situation. Concerning EMR, 3 studies did not identify size and location, 55 indication, 64 or ulceration 66 as risk factors for PPB and were not included in the meta-analysis.
Procedural details. Poor control of bleeding 18 and snaring as the final step of ESD 68 were associated with increased PPB. Piecemeal resection, although not associated with higher PPB in most studies, 13, 14, 17, 20, 22, 34, 42, 61 was associated with an increased but not statistically significant risk of bleeding (Table 4) . Additional preventive measures to reduce PPB with mucosal closure with snare and clips 69 or selective artery clipping 70 did not decrease PPB, but coagulation of visible vessels 31, 71 and use of polyglycolic acid sheets and fibrin glue 72 were associated with lower PPB rates (only in high-risk patients in the latter study). Vascularization of lesions evaluated by EUS, 73 early diet resumption, 74 and outpatient management in low-risk patients 75 were also not found to influence PPB.
Most studies found no significant differences in procedure duration between those with and without PPB. 16, 20, 21, 23, 24, [27] [28] [29] [30] [31] 33 However, procedure length greater than 75 minutes, 18 90 minutes, 26 4 hours, 36 and 5 hours 76 was associated with increased PPB in some studies. In our meta-analysis (Table 4) , procedure duration was significantly higher in patients with PPB and duration > 60 minutes was significantly associated with PPB. Medications (PPIs, H 2 RAs, and mucoprotectives). Pretreatment with PPIs before ESD was not associated with PPB reduction 11, [77] [78] [79] as well as ecabet sodium added to PPIs. 62 Bolus PPI injection for 3 days yielded similar PPB rates when compared with 72 hours' perfusion in an RCT.
14 With regard to the direct comparison between PPIs and H 2 RAs, no significant differences in PPB were reported in 3 RCTs 32, 59, 80 and in a retrospective study, 20 whereas PPB was significantly lower in the PPI group in 2 studies. 60, 81 In our meta-analysis, H 2 RAs were associated with a significantly increased PPB risk.
Operator experience and fatigue. Seven studies found no differences in PPB according to operator experience, 17, 18, 31, 36, 42, 61, 82 with only 1 study reporting significant differences in PPB between beginner (<50 ESD) and experienced (>200 ESD) operators. 33 Meta-analysis found that experience is not significantly associated with PPB (Table 4) . Regarding fatigue, ESD workload > 2 hours (but not prior other activities) was identified as a significant risk factor for early bleeding in a single study. 83 Second-look endoscopy. SLE was not performed or not reported in 30 studies, whereas SLE was routinely performed after ESD in 34 studies (mostly on the first or second day). Seven studies directly compared PPB rates in patients with and without SLE (3 RCTs and 4 retrospective studies). 20, 22, 26, 30, 34, 61, 84 The PPB rate in studies that performed SLE was not significantly different from studies that did not perform or did not report the use of SLE.
The clinical usefulness of SLE was evaluated in 7 studies (Table 4) . 20, 22, 26, 30, 34, 61, 84 PPB occurred in 59 of 1349 patients who underwent SLE (4.37%) and in 41 of 1369 patients who did not have SLE (2.99%), with no significant differences in the meta-analysis. Fourteen studies 13, 14, 17, 18, 20, 21, 23, 26, 28, 30, 34, 46, 61, 84 reported the time of bleeding in relation with SLE, and in these studies 53.3% of the bleeding episodes occurred before SLE. Prophylactic hemostasis on SLE was associated with a significantly increased risk of PPB (compared with no prophylactic hemostasis on SLE).
DISCUSSION
This systematic review and meta-analysis evaluated risk factors for PPB after endoscopic resection (EMR or ESD) for gastric superficial neoplasms. This is a noteworthy issue because the literature is controversial, and many studies are underpowered to detect small but clinically significant differences.
Previous meta-analysis reported procedure-related bleeding to occur in 4% to 9% of ESDs. [2] [3] [4] In our review, bleeding after ESD occurred in 5.1% of all procedures. We believe this is the best estimate for PPB because all studies included were selected only if a clear definition of PPB was provided and reported separately from intraprocedural bleeding.
We found that male gender, cardiopathy (and AT), cirrhosis, and chronic kidney disease were significant clinical risk factors for PPB. However, although cardiopathy was significantly associated with PPB, this increased risk is most probably associated with the use of antithrombotics. In fact, AT was associated with an increased risk of PPB (OR, 1.76). However, the difference in PPB rates was not significant in the studies that discontinued antithrombotics 1 week before and 1 week after ESD, suggesting that this may be the optimal time of AT suspension whenever possible. Additionally, we found that continuous lowdose aspirin was not associated with a significant increase in PPB in most studies. Values in bold indicate significant risk factors. PPB, Post-procedural bleeding; OR, odds ratio; PPI, proton pump inhibitor; H 2 RA, histamine-2 receptor antagonist; SLE, second-look endoscopy; RCT, randomized controlled trial. *Mean difference PPB -no PPB (95% CI).
Regarding tumor-related characteristics, tumor size > 20 mm, resected specimen size > 30 mm, localization in the lesser curvature, flat or depressed morphology, carcinoma histology, ulceration, and expanded criteria were associated with increased PPB. On the other hand, vertical localization was not found to affect overall PPB, but upper lesions were in fact associated with delayed bleeding.
Procedural factors also may be associated with increased risk of PPB, namely procedure duration > 60 minutes and the use of H 2 RA as antacid medication. Operator's experience was not found to influence PPB, although high-risk lesions are typically resected by the most experienced operators. Single studies found preventive coagulation of visible vessels as a beneficial measure in reducing PPB, and 2 recent studies suggested that polyglycolic acid sheets with fibrin glue may reduce PPB after gastric and colonic ESD. 72, 85 However, interventions like preprocedural PPIs, mucoprotectives, and routine closure with clips or artery clipping were not found to be of benefit. Endoscopic suturing of large mucosal defects after gastric and colonic ESD were also reported in a single-arm study and no adverse events were seen. 86 This systematic review may help in the selection of patients who are more likely to benefit from these developing techniques.
On the other hand, studies evaluating the benefit of preprocedural PPI and mucoprotectives had a low event rate and may be underpowered. Indeed, although mucoprotectives were associated with faster healing of the artificial ulcer in 2 recent reviews, 87, 88 its impact on PPB was not evaluated, and so it remains unclear if these faster healing decreases PPB.
SLE is routinely performed after ESD in several centers to perform hemostasis in cases of active bleeding or highrisk stigmata. Our findings clearly suggest that SLE is not associated with decreased PPB. Furthermore, more than one half of bleeding episodes occur before SLE, and even prophylactic hemostasis on SLE is not capable of reducing PPB. This suggests that even when SLE is performed, special attention should be given to patients in which prophylactic hemostasis is performed. Our findings are consistent with a recent meta-analysis limited to RCTs assessing SLE usefulness. 89 Nevertheless, it remains unclear whether a subset of patients can benefit. The results were similar in retrospective studies and RCTs, although retrospective studies could have been prone to selection bias (eg, in 1 study the decision to perform SLE was made at the discretion of the endoscopist, 30 and in another study the reasons to decide whether to perform SLE were not reported 34 ). This systematic review and meta-analysis has some limitations. First, one cannot identify interactions and confounding between risk factors, although we believe that the high number of included patients and the low heterogeneity in most evaluated risk factors allow us to draw some important conclusions. Second, the different temporal definitions of early and delayed bleeding made difficult a separate analysis of risk factors for early and delayed PPB. Third, most evidence is derived from observational studies, although subgroup analysis did not find differences according to study design and most studies were judged to have low risk of bias. Fourth, some risk factors were not strictly defined in some studies and were not stratified according to disease stage (eg, ChildPugh classification in cirrhosis) and so subgroup analyses were not possible.
To our knowledge, this is the first systematic review about risk factors for PPB after endoscopic resection of early gastric neoplasms and identified the most consistently reported risk factors. As recommendations, we suggest that (1) the definition of early and delayed bleeding should be standardized (eg, considering early bleeding < 24 hours after ESD) and (2) AT management should also be reported in detail. Based on the significant risk factors presented on Figure 2 , we also suggest that early discharge can be considered in patients with 0 to 1 risk factors. For others, hospital stay may be prolonged and the role of SLE adequately assessed. Randomized trials should be performed incorporating these risk factors in randomization and addressing the role for specific interventions such as the use, duration, and dosage of PPIs; SLE, and follow-up aiming at reducing the odds for bleeding.
In conclusion, we have identified risk factors associated with PPB after ESD that can help gastroenterologists to identify patients at increased risk. It is our hope that this can guide management, namely in terms of the adequate period of surveillance after endoscopic resection. 
